Drug Trial Radar · NCT07557355
A Study of SRSD384 in Overweight or Obese Participants
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Sirius Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).
Conditions
- Overweight , Obesity
Interventions
SRSD384 injectionDrug
Administered S.C. per the protocol
PlaceboDrug
Administered S.C. per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: 168 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NovaTrials
Charlestown, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.